团结的呼声：迈向更精确且以患者为中心的非酒精性脂肪性肝病命名法的道路。 - Suppr | 超能文献

A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.

机构信息

Diseases, 1001 North Fairfax Street 4th floor, Alexandria, VA 22314, USA.

Av. Presidente Kennedy 5488, Oficina 303, Vitacura, Santiago, Chile.

出版信息

Ann Hepatol. 2023 Jul-Aug;28(4):101115. doi: 10.1016/j.aohep.2023.101115. Epub 2023 May 22.

DOI:10.1016/j.aohep.2023.101115

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.团结的呼声：迈向更精确且以患者为中心的非酒精性脂肪性肝病命名法的道路。

Ann Hepatol. 2023 Jul-Aug;28(4):101115. doi: 10.1016/j.aohep.2023.101115. Epub 2023 May 22.

2

A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.团结的呼声：迈向更精确且以患者为中心的非酒精性脂肪性肝病命名法之路。

Hepatology. 2023 Jul 1;78(1):3-5. doi: 10.1097/HEP.0000000000000412. Epub 2023 May 22.

3

A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.团结的呼声：通往更精确且以患者为中心的非酒精性脂肪性肝病命名法之路。

J Hepatol. 2023 Jul;79(1):4-5. doi: 10.1016/j.jhep.2023.05.003. Epub 2023 May 22.

4

Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.非酒精性脂肪性肝病合并代谢功能障碍相关脂肪性肝病的预后及命名改变的意义

J Hepatol. 2021 Dec;75(6):1267-1270. doi: 10.1016/j.jhep.2021.08.020. Epub 2021 Aug 28.

5

Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease.非酒精性脂肪性肝病的转诊护理路径——为日益普遍和严重的肝病做好准备。

United European Gastroenterol J. 2021 Oct;9(8):903-909. doi: 10.1002/ueg2.12150. Epub 2021 Oct 5.

6

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.MAFLD：代谢相关脂肪性肝病的共识驱动命名建议。

Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.

7

Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease.非酒精性脂肪性肝病：一种针对心肝代谢疾病的多学科方法。

Eur J Endocrinol. 2020 Sep;183(3):R57-R73. doi: 10.1530/EJE-20-0065.

8

Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.非酒精性脂肪性肝病和 2 型糖尿病患者的发病机制、筛查方式和治疗选择。

Diabet Med. 2020 Nov;37(11):1793-1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13.

9

Non-alcoholic Fatty Liver Disease in Children.儿童非酒精性脂肪性肝病

Curr Vasc Pharmacol. 2023;21(1):4-25. doi: 10.2174/1570161121666221118155136.

10

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。

J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.

引用本文的文献

1

ORP2 regulates free cholesterol accumulation in hepatocytes during MASH.氧化还原蛋白2（ORP2）在非酒精性脂肪性肝炎（MASH）期间调节肝细胞中游离胆固醇的积累。

Hepatol Commun. 2025 Jul 14;9(8). doi: 10.1097/HC9.0000000000000737. eCollection 2025 Aug 1.

2

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.与代谢功能障碍相关脂肪性肝病相关的多态性影响终末期肝病的进展。

Gastro Hep Adv. 2024;3(1):67-77. doi: 10.1016/j.gastha.2023.09.011. Epub 2023 Oct 5.